Financing round · Healthtech
MOYOM Biotech secures financing from Cathay Consumer Co-Creation Fund
The undisclosed round supports clinical translation, additional regulatory approvals and overseas expansion.
The investing fund is managed by Cathay Capital. The announcement does not disclose the financing amount.
MOYOM plans to invest in next-generation regenerative biomaterials while expanding internationally. Its Aphranel product has China Class III registration and European MDR certification and, according to the company, entered more than 700 clinics in China after its May 2025 launch.
Use of funds
Accelerate clinical translation and pursue additional regulatory approvals
Expand into overseas markets
Continue investment in next-generation regenerative biomaterials
Funding history
Financing round · This roundUndisclosed